| Bioactivity | LSD1-IN-24(compound 3S) is a selective LSD1 inhibitor with IC50 = 0.247 μM. LSD1-IN-24 can mediate the expression of PD-L1, enhance T cell killing response, and can be used in cancer research[1]. |
| Invitro | LSD1-IN-24 (compound 3S)(0-20 μM, 5 days) 可以以 LSD1 依赖性方式降低 PD-L1 水平并以剂量依赖性方式增强 BGC-823 细胞的 T 细胞杀伤反应，但不影响 BGC-823 和 MFC 细胞增殖。此外，它可以剂量依赖性地保护 H3K4me1/2 免于去甲基化，但不能保护 H3K4me3[1]。 |
| In Vivo | LSD1-IN-24 (compound 3S) (0-50 mg/kg, oral gavage; daily for 2 weeks) 在含 MFC 细胞的皮下肿瘤模型中，以剂量依赖的方式抑制体内 MFC 细胞的生长，肿瘤的重量明显下降，肿瘤组织 Ki67 明显降低，并且对小鼠无明显毒性作用[1]。 Animal Model: |
| Name | LSD1-IN-24 |
| CAS | 4734-59-2 |
| Formula | C18H20N2OS |
| Molar Mass | 312.43 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Xing-Jie Dai, et al. Phenothiazine-Based LSD1 Inhibitor Promotes T-Cell Killing Response of Gastric Cancer Cells. J Med Chem. 2023 Mar 23;66(6):3896-3916. |